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Abstract: The present study describes the synthesis of some novel arylidene cyclic chalcones 2-(4-substituted benzylidene)-
6,6-diphenylimidazo[2,1-b][1,3]thiazole-3,5-diones and their transformation to 3-(4-substitutedphenyl)-6,6-diphenyl-3,3a- 
dihydroimidazo[2',1':2,3][1,3]thiazolo[4,5-c][1,2]oxazol-7(6H)-ones via cyclization using hydroxylamine hydrochloride. The 
starting chalcones have been synthesized by the condensation of various aromatic aldehydes and methylene entity of 
synthesized imidazothiazole-3,5-diones which were obtained by the cyclization of 5,5-diphenyl-2-thioxoimidazolidin-4-ones 
and chloroacetic acid. The intermediate 5,5-diphenyl-2-thioxoimidazolidin-4-ones have been synthesized by the  condensation 
of α-diketone (benzil) with thiourea in presence of ethanolic alkali followed by Pinacol-Pinacolone rearrangement. Structures 
of all the newly synthesized compounds were confirmed by chemical, analytical and spectral data.  
 




Nitrogen and sulphur containing heterocyles are an 
important class of organic compounds in medicinal 
chemistry, found in privileged structures 
(pharmacophores), thus the development of rapid 
synthetic routes toward focused libraries of such 
compounds is therefore of great importance to both 
medicinal and synthetic chemists. Structural 
frameworks have been described as privileged 
structures and in particular, N-containing polycyclic 
structures have been reported to be associated with a 
wide range of biological activity. Thus, fused 
heterocyclic derivatives with thiazole moiety are 
prospective objects in modern drug discovery.  
Various biologically active synthetic compounds 
have five-membered nitrogen-containing heterocyclic 
ring in their core structures. In the field of five  
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membered heterocyclic structures, imidazole nucleus 
shows versatile biological properties. The high 
therapeutic properties of the imidazole related drugs 
have encouraged the medicinal chemists to synthesize 
a large number of novel chemotherapeutic agents. 
Imidazole drugs have broadened scope in remedying 
various dispositions in clinical medicines. A lot of 
work on the synthesis and biological activities of the 
condensed imidazo [2, 1-b]-thiazoles has been 
reported. The imidazo [2, 1-b] [1, 3] thiazole skeleton 




immunosuppressive agents, herbicides, antitumor 





b]thiazole derivative, was reported as a potential 
antitumor agent in patients with small tumor burdens 
[5]. In addition, numerous imidazo[2,1-b] thiazole 
derivatives were reported to possess antitumor 
activities[6-10]. Furthermore, it was found that the 
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incorporation of pyrazole ring into different aryl or 
heteroaryl ring systems was reported to exhibit 
significant anticancer activities [11-16]. Considering 
the potent bioactivities of compounds possessing an 
imidazothiazole core, synthesizing new imidazo [2, 1-
b] [1, 3] thiazole derivatives efficiently attracted our 
attention
 
[17-18]. In the present study we wish to 
report the synthesis of some novel fused imidazo [2, 1-
b] [1, 3] thiazole derivatives. On the other hand 
thiazoles are basic class of heterocyclic moieties which 
possess a wide range of therapeutic interest and their 
importance is also very much-established in medicine
 





[22-23], anti HIV agents
 
[24]. Among the important heterocyclic compounds 
1,3,4-thiadiazoles are one of the important structural 
fragments in medicinal chemistry due to their various 







activity,[27] anti-infective agents,[28] 
antibacterial,[29] antidepressants,[30] anti-cancer 
agents.[31] 
Since the discovery of heterocyclic nucleus, the 
chemistry of isoxazole and their fused derivatives 
continue to draw attention of organic chemists due to 
their various biological activities such as 
antithrombotic agents [32], antitumor activity [33], 
antinociceptive activity activity [34], anti-
inflammatory activity [35], anti-oxidants [36], 
antibacterial [37], antifungal [38], nematicidal agents 
[39], antifungal [40], anti-inflammatory and 
hypoglycaemic agents [41]. We planned to undertake 
the synthesis and characterization of some fused 
imidazole containing thiazolo-isoxazole derivatives 
carrying the above biodynamic heterocyclic systems 
with the hope to achieve some novel systems. All the 





C-NMR spectroscopy and mass 
spectrometry. 
Results and discussion  
Simple base catalyzed condensation of α-diketone 
(benzil), with thiourea in absolute ethanol furnished 
5,5-diphenyl-2-thioxoimidazolidin-4-one (1) followed 
by pinacol-pinacolone type rearrangement. Formation 
of this product was confirmed by IR spectrum at 3294 
cm
-1 
indicates the presence of NH group of amide 
moiety. The other band at 3236 cm
-1 
also indicates the 
presence of NH in (Ph)2C-NH CO.
 1
H-NMR spectrum 
shows two singlet’s at δ 9.9 and δ 9.1, which would be 
assigned for NH proton of amide. It was condensed 
with chloroacetic acid  and glacial acetic acid in 
presence of anhydrous sodium acetate to yield the 6,6-
diphenylimidazo[2,1-b][1,3]thiazole-3,5(2H,6H)-dione 
(2) . Its structure was confirmed by the appearance of 
singlet at δ 3.6 for CH2 of thizole ring and 
disappearance of NH signal in 
1
H NMR spectra. The 
condensation of (2) with various 4-substituted 
araldehydes (3)  in presence of anhydrous sodium 
acetate and glacial acetic acid afforded corresponding 
2-(4-subsituted phenyle)-6,6-diphenylimidazo[2,1-
b][1,3]thiazole-3,5(2H,6H)-diones (4a-d). Reaction of 
hydroxylamine hydrochloride on these Compounds 
(4a-d) underwent  cyclocondensation  reaction afforded 
3-(4-substitutedphenyl)-6,6-diphenyl-3,3a-dihydro 
imidazo[2',1':2,3][1,3]thiazolo[4,5-c][1,2] oxazol-
7(6H)-ones (5a-d). The structures of these compounds 





H NMR spectra at  5.2 corresponding to the –
CH-Ar proton of the isoxazole ring.  The 
13
C NMR 
spectra of compounds (5a-d) were recorded in DMSO-
d6. The prominent signals corresponding to the 
carbons of thiazolo-isoxazole ring in all compounds 
observed nearly at 48.5, 50.1 and 154.4 ppm, are proof 
of further evidence of their structures (Scheme 1 and 
Scheme 2). 
Experimental 
General Procedures  
   All the melting points were determined in open 
capillary tube and are uncorrected. The IR spectra were 
recorded on Perkin-Elmer spectrometer. The 
1
H NMR 
spectra were scanned on a DRX-300 MHz. 
spectrometer (300 MHz) in CDCl3/DMSO-d6 using 
TMS as internal standard and chemical shifts are 
expressed in δ ppm. The mass spectra were recorded 
on Jeol SX-102 (FAB). m-Nitrobenzyl alcohol (NBA) 
was used as a matrix. Purity of synthesized compounds 
was checked by TLC using silica gel-G. Spots were 
exposed in an iodine chamber. Compound 6 was 
synthesized by literature method [30]. 
Synthesis of 5,5-diphenyl-2-thioxoimidazolidin-4-
one (1):  
Benzil (0.05 mol), thiourea (0.05 mol) and 15 ml of 
30% aq. NaOH was refluxed in  75 ml of ethanol for 2 
h. After the completion of the reaction (monitored by 
TLC), it was allowed to cool and poured in to crushed 
ice with constant stirring. Solid separated was filtered 
off and removed as insoluble by product. The filtrate 
was acidified with dil. HCl resulted solid precipitate, 
which was filtered, dried and recrystallized from 
ethanol afforded analytical samples of (1). 
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Yield 94 %, m.p.136 
o
C ; IR (KBr) cm
-1
: 3255 ( N-H 
amide, CO-NH-CS); 3135 (N-H, CPh2-NH-CS); 3010 





(DMSO d6) δ: 6.9-7.6 (m, 10H, Ar-H, J = 9 Hz), δ 9.9 
(s, 1H, NH, CO-NH-CO); δ 9.1 (s, 1H, NH, CO-NH-
CPh2); 
13
C -NMR (DMSO) δ: 180.6, 174.5, 139.7, 
129.1, 128.7, 126.7,  73.8; Anal.Calcd. For 
C15H12N2OS: C, 67.16; N, 10.44; S,11.94 %. Found C, 




b][1,3]thiazole-3,5(2H,6H)-dione (2):   
A mixture of 1 (0.01 mol) and chloroacetic acid 
(0.01 mol) was dissolved in gl. acetic acid and to this 
solution (0.02 mol) of anhydrous sodium acetate was 
added, and reaction mixture was refluxed for 8 h. After 
the completion of the reaction (monitored by TLC), the 
reaction mixture was cooled and poured in to ice cold 
water with stirring. The solid formed was filtered and 
crystallized from ethanol afforded analytical sample of 
(2).  
Yield 89%, m.p.162 
o
C ; IR (KBr) cm
1
: 3045 (C-H 
Ar-H); 2952 (C-H,CH2), 1695 (C=O ), 1594 (C=N); 
1
H 
NMR (DMSO d6) δ: 7.8-7.2 (m, 10H, Ar-H, J = 8.7 Hz 
),3.6 (s,CH2, thizole); 
13
C -NMR (DMSO d6) δ: 167.2, 
170.0, 162.5, 143.1, 129.2, 128.1, 126.1, 73.0, 32.7 : 
Anal.Calcd. For C17H12N2O2S: C, 66.32; N, 9.09; S, 




 Synthesis of (2Z)-2-(4-substitutedbenzylidene)-6,6-
diphenylimidazo[2,1-b][1,3]thiazole-3,5(2H,6H)-
diones (4a-d): 
An equimolar mixture of 2 (0.01mol) and 4-
chlorobenzaldehyde 3a (0.01mol) in glacial acetic acid 
was taken in a round bottom flask and anhydrous 
sodium acetate (0.02 mol) was added and refluxed for 
8 h.  After completion of the reaction, (progress of the 
reaction was accessed by TLC) reaction mixture was 
allowed to cool and solid separated was recrystallized 
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Scheme1: Synthesis of the title compounds 
 
 



























































Scheme 2: Mechanism of Thiohydentoin Synthesis 




Yield 84%, m.p.189 
o
C ; IR (KBr) cm
-1
: 3025 (C-H, 
Ar-H), 1691 (C=O ), 1590 (C=N), 758 (C-Cl) ; 
1
H 
NMR (DMSO d6) δ: 7.6-7.7 (m, 14H, Ar-H, J = 8.4 
Hz), 6.1 (s, 1H,=CH-Ar);
 13
C -NMR (DMSO d6) δ: 
171.0, 166.3, 163.0, 142.0, 140.1, 132.2, 129.2, 
128.8,127.1, 126.3, 124.2,122.5,121.3, 120.6, 80.0; 
Anal.Calcd.For C24H15ClN2O2S; C,66.97; N,6.51, S 
,7.44 %. Found C, 66.54; N, 6.45; S, 7.24 %. MS:m/z 
430 [M]
 +





Yield 81%, m.p.180 
o
C ; IR (KBr) cm
-1
: 3027 (C-H, 
Ar-H), 1693 (C=O ), 1594 (C=N); 
1
H NMR (DMSO 
d6) δ: 7.5-7.6 (m, 14H, Ar-H, J = 8.4 Hz), 6.0 (s, 
1H,=CH-Ar).
 13
C -NMR (DMSO d6) δ: 170.6, 165.9, 
162.8, 142.1, 139.6, 132.1, 129.0, 128.6, 
127.1,126.1,123.4,121.9,121.2, 120.2, 78.3. 
Anal.Calcd.For C24H15N2O2S; C,72.72; N,7.07; S, 8.08 






dione (4c):   
Yield 83%, m.p.184 
o
C ; IR (KBr) cm
-1
: 3028 (C-H, 
Ar-H), 1687(C=O), 1589 (C=N), 1098 (C-O); 
1
H NMR 
(DMSO d6) δ :7.6-7.7 (m, 14H, Ar-H, J = 8.8 Hz), 6.0 
(s,1H,=CH-Ar) 3.6 (3H,s,OCH3).
 13
C - NMR (DMSO 
d6) δ: 170.4, 166.1, 163.1,141.3, 139.1, 132.2, 128.16, 
127.9, 127.3, 125.9,123.2,122.6,121.3, 120.2, 56.7, 
78.1, Anal.Calcd.For C25H18N2O3S; C,70.40; N,6.27; 




Synthesis of  2-[4-(N,N dimethylamino) 
benzylidene]-6,6-diphenylimidazo[2,1-b][1,3] 
thiazole-3,5(2H,6H)-dione (4d):  
Yield 87%, m.p.182 
o
C ; IR (KBr) cm
-1
: 3043 (C-H, 
Ar-H), 1681 (C=O ), 1584 (C=N); 
1
H NMR (DMSO 
d6) δ: 7.3-7.5 (m, 14H, Ar-H, J = 8.5 Hz), 6.1 (s, 
1H,=CH-Ar), 3.1 (6H,s,N(CH3)2; 
13
C -NMR (DMSO 
d6) δ:171.1, 166.1,162.9, 141.4, 139.2, 132.5, 128.3, 
127.8, 127.1, 125.6, 119.9, 56.4, 78.3, 43.7;  
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Anal.Calcd.For C26H21N3O2S; C,71.07;  N,9.56;  







Anhydrous sodium acetate (0.02mole) was dissolved 
in hot acetic acid. Compound (4a, 0.01 mole) and 
hydroxylamine hydrochloride (0.01 mole) were taken 
in absolute alcohol (20 mL). The solution of sodium 
acetate in acetic acid was transferred to the reaction 
mixture and refluxed for 8-10 h. After completion of 
the reaction (monitored by TLC), the reaction mixture 
was cooled, diluted with water and kept under 
refrigeration. The resulting compounds were filtered 
and recrystallized from ethanol afforded analytical 
samples of 5a-d in good yields. 
Synthesis of 3-(4-chlorophenyl)-6,6-diphenyl-3,3a-
dihydroimidazo[2',1':2,3][1,3] thiazolo[4,5-
c][1,2]oxazol-7(6H)-one (5a):  




: 3048 (C-H, 
Ar-H), 1726 (C=O), 1524  (C=N), 1180 (C-O),747 (C-
Cl); 
1
H NMR (DMSO d6) δ : 7.1-7.8 (m, 14H, Ar-H, J 
= 8.8 Hz), 5.2 (d,1H,-CH-Ar, J = 3.2 Hz) 3.6 (1H,-CH-
S, J = 3.2 Hz );
 13
C -NMR (DMSO d6) δ: 212.4, 164.0, 
154.4,144.0, 140.5, 139.2, 132.8, 129.2, 128.4, 128.8, 
128.0, 122.9, 80.1,48.5,50.1; Anal.Calcd. For 
C24H16ClN3O2S; C, 64.71; N, 9.43; S, 7.17 %. Found 






 Synthesis of 3,6,6-triphenyl-3,3a-
dihydroimidazo[2',1':2,3][1,3]thiazolo[4,5-
c][1,2]oxazol-7(6H)-one (5b): 
Yield 58 %, m.p.205 
o
C; IR (KBr) cm
-1 
3042 (C-H, 
Ar-H), 1724 (C=O), 1528 (C=N); 
1
H NMR (DMSO d6) 
δ : 6.9-7.6 (m, 15, Ar-H, J = 8.4 Hz), 4.5 (d,1H,-CH-
Ar, J = 3.1 Hz), 3.4 (d,1H,-CH-S, J = 3.1 Hz) ;
 13
C-
NMR (DMSO d6) δ: 205.0, 161.3, 151.3, 143.8, 140.2, 
139.4, 131.4, 128.3, 128.8,  127.0, 127.8, 126.0, 79.9, 
47.1, 49.1; Anal.Calcd.For C24H17N3O2S; C,70.71; 
N,10.21; S ,7.79%. Found C,69.72; N,12.40; S, 7.57 






Yield 52 %, m.p.228 
o
C  ; IR (KBr) cm
-1 
  3047 (C-H 
Ar-H), 1731 (C=O ), 1532 (C=N), 1103 (C-O) ; 
1
H 
NMR (DMSO d6) δ : 6.7-7.1 (m, 14H, Ar-H, J = 8.9 
Hz), 6.6 (s, 1H,NH),4.5 (d,1H,-CH-Ar, J = 3.4 Hz), 3.3 
(d,1H,-CH-S, J = 3.6 Hz), 3.6 (3H,s,OCH3);
13
C-NMR 
(DMSO d6) δ: 208.3, 154.2, 164.0, 143.8, 140.4, 139.2, 
132.1, 130.3, 128.6, 129.1, 127.7, 126.7,  79.1,  55.9, 
47.6, 49.3; Anal.Calcd.For  C25H19N3O3S; C,68.18;  
N,9.52; S ,7.27 %. Found C, 67.80; N, 12.34; S, 6.87 
%. MS:m/z 441 [M]
 +
.   
Synthesis of 3-(4-(N,N dimethylamino phenyl)-6,6-
diphenyl-3,3a-dihydroimidazo [2',1':2,3] [1,3] 
thiazolo[4,5-c][1,2]oxazol-7(6H)-one (5d): 
Yield 48 %, m.p.219 
o
C ; IR (KBr) cm
-1 
 3039 (C-H, 
Ar-H), 1724 (C=O ), 1562 (C=N) ; 
1
H NMR (DMSO 
d6) δ : 6.9-7.4 (m, 14H, Ar-H, J = 9.0 Hz), 6.5 (s, 
1H,NH), 4.3 (d,1H,-CH-Ar, J = 3.5 Hz), 3.4 (d,1H,-
CH-S, J = 3.4 Hz), 3.1 (6H, s, N(CH3)2; 
13
C -NMR 
(DMSO d6) δ:173.2, 154.5, 164.7, 143.6, 140.2, 139.1, 
132.1, 130.4, 128.5, 129.5, 127.7, 126.1, 79.3, 55.6, 
47.8; Anal.Calcd.For C26H22N4O2S; C, 68.72 ; N,12.33 





In the present paper our aim has been verified by the 
synthesis of some novel fused 3-(4-substitutedphenyl)-
6,6-diphenyl-3,3a-dihydroimidazo [2',1': 2,3] [1,3] 
thiazolo [4,5-c] [1,2] isoxazoles, in which imidazole 
and thiazolo-isoxazole moieties are present as the part 
of same molecular framework. 
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